Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics
PharmaTech
JUNE 24, 2025
Some companies are combining mRNA vaccines with programmed cell death protein 1 (PD-1) inhibitors to activate the immune system and elicit tumour-specific T-cell responses. The LNPs provide targeted delivery of the mRNA directly to tumours, resulting in strong immune activation, tumour elimination, and durable immunological responses.
Let's personalize your content